Breast Cancer

The addition of palbociclib to adjuvant endocrine therapy did not extend invasive DFS for patients with early hormone receptor-positive, HER2-negative breast cancer, according to results presented at San Antonio Breast Cancer Symposium.

A liquid biopsy-based approach to treatment selection improved outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

Use of genomics to guide treatment selection improved outcomes for certain patients with metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.

Black and Hispanic women appeared more likely than white women to develop breast cancer-related lymphedema, according to study results presented at San Antonio Breast Cancer Symposium.

Elacestrant improved outcomes compared with standard endocrine therapy for certain women with pretreated ER-positive, HER2-negative metastatic breast cancer, according to results presented at San Antonio Breast Cancer Symposium.

Christian S. Hinrichs, MD, is reluctant to give cancer credit for anything good.

Representatives of San Antonio Breast Cancer Symposium and American Association for Cancer Research will honor two individuals for their significant contributions to breast cancer research.

The William L. McGuire Lecture Award will be presented to Olufunmilayo Olopade, MD, FAACR, at San Antonio Breast Cancer Symposium this month.

Premenopausal women with node-positive breast cancer and low recurrence scores benefited from adjuvant chemotherapy, whereas postmenopausal women did not, according to results of a study published in The New England Journal of Medicine.

The FDA granted priority review to olaparib for adjuvant treatment of certain patients with high-risk breast cancer.